Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study-Reference-Cited by-同舟云学术

Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study

Published:2004-11-16 Issue:3 Volume:55 Page:271-276
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Schena M.,Barone C.,Birocco N.,Dongiovanni D.,Numico G.,Colantonio I.,Bertetto O.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-004-0875-1.pdf

Reference30 articles.

1. Boring CG, Squires TS, Tong T (1992) Cancer statistics 1992. CA Cancer J Clin 42:19?38

2. Zbaren P, Lehmann W (1987) Frequency and sites of distant metastases in head and neck squamous-cell carcinoma. Arch Otolaryngol Head Neck Surg 113:762?764

3. Vokes EE, Weichselbaum RR, Lippman S, et al (1993) Head and neck cancer. N Engl J Med 328:184?194

4. Morton RP, Rugman F, Dorman EB, et al (1985) Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 15(3):283?289

5. Forastiere AA, Metch B, Schuller DE, et al (1992) Randomized comparison of cisplatin plus 5-fluorouracil versus carboplatin plus 5FU versus methotrexate in advanced squamous cell carcinoma of the head and neck. Clin Oncol 10(8):1245?1251

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Silmitasertib-induced macropinocytosis promoting DDP intracellular uptake to enhance cell apoptosis in oral squamous cell carcinoma;Drug Delivery;2021-01-01

2. Palliative treatment of patients with inoperable locally advanced, recurrent or metastatic head and neck squamous cell cancer, using a low-dose and personalized chemotherapeutic regimen;Oncology Letters;2017-04-21

3. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study;Oral Oncology;2016-11

4. An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer;Journal of Medicinal Chemistry;2015-12-01

5. Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma;OncoTargets and Therapy;2013-10